CytomX Therapeutics Cash on Hand 2014-2022 | CTMX
CytomX Therapeutics cash on hand from 2014 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
CytomX Therapeutics Annual Cash on Hand (Millions of US $) |
2021 |
$305 |
2020 |
$316 |
2019 |
$296 |
2018 |
$436 |
2017 |
$374 |
2016 |
$182 |
2015 |
$187 |
2014 |
$64 |
2013 |
$9 |
CytomX Therapeutics Quarterly Cash on Hand (Millions of US $) |
2022-09-30 |
$194 |
2022-06-30 |
$228 |
2022-03-31 |
$263 |
2021-12-31 |
$305 |
2021-09-30 |
$236 |
2021-06-30 |
$266 |
2021-03-31 |
$394 |
2020-12-31 |
$316 |
2020-09-30 |
$321 |
2020-06-30 |
$346 |
2020-03-31 |
$248 |
2019-12-31 |
$296 |
2019-09-30 |
$326 |
2019-06-30 |
$349 |
2019-03-31 |
$397 |
2018-12-31 |
$436 |
2018-09-30 |
$465 |
2018-06-30 |
$335 |
2018-03-31 |
$361 |
2017-12-31 |
$374 |
2017-09-30 |
$331 |
2017-06-30 |
$336 |
2017-03-31 |
$163 |
2016-12-31 |
$182 |
2016-09-30 |
$178 |
2016-06-30 |
$196 |
2016-03-31 |
$181 |
2015-12-31 |
$187 |
2015-09-30 |
$114 |
2015-06-30 |
|
2015-03-31 |
|
2014-12-31 |
|
2014-09-30 |
|
2013-12-31 |
$9 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.122B |
$0.070B |
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|